Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.70 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.70 |
| ▸ | LMNA | P02545 | 4/20 | 0.69 |
| ▸ | PRKCA | P17252 | 4/20 | 0.60 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.60 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.60 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | DGKA | P23743 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26973 | 1.00 | MAPT (0.70) | MAPTMAPK1LMNAPRKCAPRKCE | |
| SCHEMBL343318 | 1.00 | MAPT (0.70) | MAPTMAPK1LMNAPRKCAPRKCE | |
| SCHEMBL16701295 | 1.00 | MAPT (0.70) | MAPTMAPK1LMNAPRKCAPRKCE | |
| SCHEMBL571263 | 1.00 | MAPT (0.70) | MAPTMAPK1LMNAPRKCAPRKCE | |
| SCHEMBL20263545 | 1.00 | MAPT (0.70) | MAPTMAPK1LMNAPRKCAPRKCE | |
| SCHEMBL1695881 | 1.00 | MAPT (0.70) | MAPTMAPK1LMNAPRKCAPRKCE | |
| SCHEMBL1246202 | 0.98 | MAPT (0.67) | MAPTMAPK1LMNAPRKCAPRKCE | |
| SCHEMBL9011176 | 0.92 | MAPT (0.58) | MAPTMAPK1LMNAPRKCAPRKCE | |
| Propene SCHEMBL20819808 | 0.92 | MAPT (0.60) | MAPTMAPK1LMNAPRKCAPRKCE | |
| SCHEMBL144890 | 0.90 | PRKCA (0.66) | MAPTMAPK1LMNAPRKCAPRKCE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119604309-A | External composition | 花王株式会社 | 2025-03-11 | — | — | CN | disclosed |
| US-20240277668-A1 | HISTAMINE RECEPTOR AGONISTS FOR CANCER THERAPY IN CANCER PATIENTS UNRESPONSIVE TO CANCER IMMUNOTHERAPY AND WITH ELEVATED MYELOID DERIVED SUPPRESSOR CELLS | TSP THERAPEUTICS INC. | 2024-08-22 | — | — | US | disclosed |
| EP-4376835-A1 | HISTAMINE RECEPTOR AGONISTS FOR CANCER THERAPY IN CANCER PATIENTS UNRESPONSIVE TO CANCER IMMUNOTHERAPY AND WITH ELEVATED MYELOID DERIVED SUPPRESSOR CELLS | TSP Therapeutics Inc. (US) | 2024-06-05 | — | — | EP | disclosed |
| WO-2023009261-A1 | HISTAMINE RECEPTOR AGONISTS FOR CANCER THERAPY IN CANCER PATIENTS UNRESPONSIVE TO CANCER IMMUNOTHERAPY AND WITH ELEVATED MYELOID DERIVED SUPPRESSOR CELLS | PAZ ALBERTO (US) | 2023-02-02 | — | — | WO | disclosed |
| EP-3528799-A1 | PHARMACEUTICAL COMPOSITIONS OF 5-HYDROXY-2-METHYLNAPHTHALENE-1, 4-DIONE | Pellficure Pharmaceuticals, Inc. (US) | 2019-08-28 | — | — | EP | disclosed |
| WO-2018195202-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | PELLFICURE PHARMACEUTICALS INC. (US) | 2018-10-25 | — | — | WO | disclosed |
| US-20180221306-A1 | PHARMACEUTICAL COMPOSITIONS OF 5-HYDROXY-2-METHYLNAPHTHALENE-1,4-DIONE | PELLFICURE PHARMACEUTICALS, INC. | 2018-08-09 | — | — | US | disclosed |
| WO-2018080933-A1 | PHARMACEUTICAL COMPOSITIONS OF 5-HYDROXY-2-METHYLNAPHTHALENE-1, 4-DIONE | PELLFICURE PHARMACEUTICALS INC. (US) | 2018-05-03 | — | — | WO | disclosed |
| EP-1604647-B1 | Cosmetic composition containing polyorganosiloxane-containing epsilon-polylysine polymer, and polyhydric alcohol, and production thereof | CHISSO CORP (JP) | 2008-05-07 | — | — | EP | disclosed |
| US-20060018867-A1 | Cosmetic composition and production thereof | ICHIMARU PHARCOS CO., LTD | 2006-01-26 | — | — | US | disclosed |
| EP-1604647-A1 | Cosmetic composition containing polyorganosiloxane-containing epsilon-polylysine polymer, and polyhydric alcohol, and production thereof | Ichimaru Pharcos Co., Ltd. (JP) | 2005-12-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180221306-A1 | PHARMACEUTICAL COMPOSITIONS OF 5-HYDROXY-2-METHYLNAPHTHALENE-1,4-DIONE | DHPS, SRD5A2, SRD5A1 | MAPT 2239/4885MAPK1 4529/4885LMNA 974/4885 |
| US-20060018867-A1 | Cosmetic composition and production thereof | CUTA, PARG, TYR | MAPT 2549/4885MAPK1 3374/4885LMNA 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.